Business Context and Reporting Period
This Form 8-K is a current report filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on July 22, 2021, with a signature date of July 26, 2021. The filing primarily reports the results of the Company's 2021 Annual Meeting of Stockholders held on July 22, 2021, and includes a Regulation FD disclosure regarding a merger partner.
Key Financial Metrics
This filing is a current report regarding corporate governance and regulatory disclosures. It does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
The filing details the outcomes of two proposals voted on by stockholders at the Annual Meeting. As of the record date (June 7, 2021), there were 47,371,482 shares outstanding, with 33,963,382 shares present or represented by proxy, establishing a quorum.
- Proposal 1 (Election of Directors): Stockholders elected two Class I director nominees, Caley Castelein, M.D., and Cheryl Cohen.
- Caley Castelein, M.D.: 20,859,073 votes For; 3,908,603 votes Withhold; 9,195,706 Broker Non-Votes.
- Cheryl Cohen: 20,886,608 votes For; 3,881,068 votes Withhold; 9,195,706 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Results: 33,161,694 votes For; 770,446 votes Against; 31,242 votes Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Regulatory Disclosure
Under Item 7.01 (Regulation FD Disclosure), the Company referenced a press release issued on July 26, 2021, by its merger partner, Aadi Bioscience, Inc. The release announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review for the New Drug Application (NDA) of FYARRO for the treatment of advanced malignant PEComa. The filing explicitly states that this information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the corporate identity: The filing is for Aerpio Pharmaceuticals, Inc. (Ticker: ARPO), not Whitehawk Therapeutics, Inc.
- Confirm the status of the merger with Aadi Bioscience, Inc., given the reference to Aadi's FDA Priority Review for FYARRO.
- Review the Definitive Proxy Statement filed on June 9, 2021, for detailed background on the director nominees and auditor ratification.
- Note that no financial performance data is contained in this specific 8-K filing; refer to the most recent 10-K or 10-Q for financial metrics.